Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon

被引:120
作者
Reichard, O
Glaumann, H
Frydén, A
Norkrans, G
Wejstål, R
Weiland, O
机构
[1] Danderyd Hosp, Dept Infect Dis, Stockholm, Sweden
[2] Huddinge Univ Hosp, Karolinska Inst, Dept Infect Dis, Stockholm, Sweden
[3] Linkoping Univ Hosp, S-58185 Linkoping, Sweden
[4] Sahlgrens Univ Hosp, Gothenburg, Sweden
[5] Huddinge Univ Hosp, Karolinska Inst, Dept Pathol, Stockholm, Sweden
关键词
follow-up; long-term; histological; interferon therapy; virological;
D O I
10.1016/S0168-8278(99)80129-9
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: This study aimed to determine the long-term outcome of hepatitis C virus (HCV)-infected patients who respond to interferon treatment with clearance of serum HCV RNA. Methods: We performed a long-term biochemical, virological, and histological follow-up of all sustained virological responders, defined as those who became HCV RNA negative at follow-up 6 months after the end of treatment, from 3 controlled interferon trials performed in Sweden between 1988 and 1994, Results: At biochemical and virological long-term follow-up performed in 26 sustained virological responders 3.5-8.8 years (mean+/-SD, 5.4+/-1.6 years) after the end of IFN therapy, 22 patients (85%) had normal serum ALT levels, and 24 patients (92%) were HCV RNA negative in serum, Liver biopsies performed in 23 patients 2.1-8.7 years (mean+/-SD, 5,0+/-1,8 years) after end of treatment showed no or minimal inflammation, whereas mild and probably irreversible fibrosis was seen in a few patients, Conclusion: In this well-defined material of sustained responders to IFN therapy, the long-term prognosis was excellent, Nearly all had a durable response, not only biochemically and virologically, but more importantly also histologically with normalisation or near normalisation of previous histological lesions.
引用
收藏
页码:783 / 787
页数:5
相关论文
共 32 条
[1]  
[Anonymous], 1997, HEPATOLOGY, V26, pS2
[2]   PILOT-STUDY OF COMBINATION THERAPY WITH RIBAVIRIN PLUS INTERFERON-ALFA FOR INTERFERON ALFA-RESISTANT CHRONIC HEPATITIS-C [J].
BRILLANTI, S ;
GARSON, J ;
FOLI, M ;
WHITBY, K ;
DEAVILLE, R ;
MASCI, C ;
MIGLIOLI, M ;
BARBARA, L .
GASTROENTEROLOGY, 1994, 107 (03) :812-817
[3]   Long-term course of interferon-treated chronic hepatitis C [J].
Cammà, C ;
Di Marco, V ;
Lo Iacono, O ;
Almasio, P ;
Giunta, M ;
Fuschi, P ;
Vaccaro, A ;
Fabiano, C ;
Magrin, S ;
Di Stefano, R ;
Bonura, C ;
Pagliaro, L ;
Craxì, A .
JOURNAL OF HEPATOLOGY, 1998, 28 (04) :531-537
[4]   RIBAVIRIN IN THE TREATMENT OF CHRONIC HEPATITIS-C UNRESPONSIVE TO ALFA INTERFERON [J].
CAMPS, J ;
GARCIA, N ;
RIEZUBOJ, JI ;
CIVEIRA, MP ;
PRIETO, J .
JOURNAL OF HEPATOLOGY, 1993, 19 (03) :408-412
[5]  
CHEMELLO L, 1995, HEPATOLOGY, V22, P700, DOI 10.1016/0270-9139(95)90286-4
[6]   Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C [J].
Chemello, L ;
Cavalletto, L ;
Donada, C ;
Bonetti, P ;
Casarin, P ;
Urban, F ;
Bernardinello, E ;
Pontisso, P ;
Alberti, A .
GASTROENTEROLOGY, 1997, 113 (05) :1654-1659
[7]  
DAVIS GL, 1994, CLIN THER, V16, P334
[8]   TREATMENT OF CHRONIC HEPATITIS-C WITH RECOMBINANT INTERFERON-ALFA - A MULTICENTER RANDOMIZED, CONTROLLED TRIAL [J].
DAVIS, GL ;
BALART, LA ;
SCHIFF, ER ;
LINDSAY, K ;
BODENHEIMER, HC ;
PERRILLO, RP ;
CAREY, W ;
JACOBSON, IM ;
PAYNE, J ;
DIENSTAG, JL ;
VANTHIEL, DH ;
TAMBURRO, C ;
LEFKOWITCH, J ;
ALBRECHT, J ;
MESCHIEVITZ, C ;
ORTEGO, TJ ;
GIBAS, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) :1501-1506
[9]  
DI BA, 1989, NEW ENGL J MED, V321, P1506
[10]   Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis [J].
Foster, GR ;
Goldin, RD ;
Thomas, HC .
HEPATOLOGY, 1998, 27 (01) :209-212